Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its position in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 9.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 142,693 shares of the company’s stock after selling 14,400 shares during the period. Los Angeles Capital Management LLC’s holdings in Acelyrin were worth $703,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. grew its position in Acelyrin by 118.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after acquiring an additional 3,921 shares during the period. Principal Financial Group Inc. acquired a new stake in Acelyrin during the 2nd quarter worth approximately $49,000. SG Americas Securities LLC purchased a new position in Acelyrin in the second quarter valued at approximately $51,000. Nisa Investment Advisors LLC lifted its position in Acelyrin by 58,570.8% during the second quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company’s stock valued at $62,000 after buying an additional 14,057 shares in the last quarter. Finally, US Bancorp DE grew its stake in Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock worth $83,000 after buying an additional 7,336 shares during the period. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Acelyrin Price Performance

Shares of Acelyrin stock opened at $4.69 on Friday. Acelyrin, Inc. has a 1-year low of $3.36 and a 1-year high of $9.20. The business has a 50-day moving average of $5.40 and a 200-day moving average of $5.01. The company has a market capitalization of $468.11 million, a PE ratio of -1.90 and a beta of 1.98.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). During the same quarter in the previous year, the business posted ($0.56) earnings per share. On average, equities analysts expect that Acelyrin, Inc. will post -3.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on SLRN. HC Wainwright raised their target price on shares of Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Thursday. Wells Fargo & Company raised their price objective on Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. Piper Sandler decreased their target price on Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Morgan Stanley dropped their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, August 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.